Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Ultra Short Income ETF (JPST) vs Medpace Holdings Inc (MEDP) Price & Performance

JPMorgan Ultra Short Income ETFTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

JPMorgan Ultra Short Income ETF vs Medpace Holdings Inc — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.49, while Medpace Holdings Inc trades at $532.89 (market cap $15.08B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.

JPSTMEDP
Sector
Leveraged / InverseTechnology
52-Week High
$50.78$620.59
52-Week Low
$50.40$308.88
Market Cap
$15.08B
Enterprise Value
$14.55B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Ultra Short Income ETF

JPST trades at $50.49, showing minimal daily movement with a slight decline of $0.01 (-0.02%). The technical outlook is bearish based on moving averages, while oscillators signal neutrality. Recent news highlights institutional interest, with Greenwood Gearhart LLC increasing its holdings by 9.6% as of July 2026. The ETF focuses on ultra-short income, offering a cash alternative with low duration risk, as noted in Seeking Alpha analysis from April 2026.

The outlook for JPST remains stable, appealing to risk-averse investors seeking capital preservation and modest income through dividends. Key risks include interest rate sensitivity and macroeconomic shifts affecting short-term bonds. Institutional accumulation supports confidence, but the bearish technical signal warrants caution for short-term traders.

Medpace Holdings Inc

MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.

MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.

Returns comparison

Trailing returns across standard periods

About JPMorgan Ultra Short Income ETF

JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.

Read more on JPST

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP